For Men With Prostate Cancer

Now Enrolling: Solar Clinical Trials

Your patients undergoing staging for newly diagnosed prostate cancer or with suspected biochemical recurrent prostate cancer are invited to participate in Phase 3 clinical trials testing the diagnostic performance of copper Cu 64 PSMA I&T, a new agent for positron emission tomography (PET)/computed tomography (CT) imaging.

Solar-Stage, for staging of men with newly diagnosed unfavorable intermediate-risk, high-risk, or very-high-risk prostate cancer

Solar-Recur, for detection in men with suspected biochemical recurrence of prostate cancer

Copper Cu 64 PSMA I&T PET/CT imaging could be useful at different stages of a patient’s prostate cancer journey.
Please see each trial page for more information about eligibility.

Typical prostate cancer treatment journey

About Copper Cu 64 PSMA I&T PET/CT

What Is Copper Cu 64 PSMA I&T PET/CT?

Copper Cu 64 PSMA I&T is a radioactive PET/CT imaging agent that specifically targets the prostate-specific membrane antigen (PSMA) protein, which is overexpressed in metastatic prostate cancers.

Copper Cu 64 has a longer half-life (12.7 hours) and shorter positron emission range than many other isotopes, which could enable high-quality image resolution.^1,2

Clinical Development Overview

Copper Cu 64 PSMA I&T PET/CT has been investigated in a Phase 1/2 study of 38 men with recurrent metastatic prostate cancer.
It was determined in the Phase 2 trial that a single dose of 7-9 mCi copper Cu 64 PSMA I&T PET/CT enabled detection and localization of prostate lesions with sufficient image quality for diagnostic purposes.
Copper Cu 64 PSMA I&T PET/CT was well tolerated in these studies, with no treatment-related adverse events and no changes in measured safety parameters.
The Phase 3 studies of copper Cu 64 PSMA I&T, a radiopharmaceutical, are being performed for research purposes only. The safety and effectiveness of copper Cu 64 PSMA I&T have not been established by the United States Food and Drug Administration. The medical benefits and risks of this agent are under investigation.

Solar-Stage, for staging of men with newly diagnosed unfavorable intermediate-risk, high-risk, or very-high-risk prostate cancer

Solar-Recur, for detection in men with suspected biochemical recurrence of
prostate cancer

Contact Us

For more information on eligibility and enrollment in the Solar-Stage or Solar-Recur clinical trials, please contact us using the form below.

More information is also
available at ClinicalTrials.gov
(Solar-Stage: NCT06235151,
Solar-Recur: NCT06235099).

ERROR

Thank You

Your form was
submitted successfully.
We will respond to you soon.

References

Jødal L, Le Loirec C, Champion C. Positron range in PET imaging: non-conventional isotopes. Phys Med Biol. 2014;59(23):7‍41‍9-‍743‍4. doi:10.10‍8‍8/00‍31-9‍15‍5/59/23/7419

Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016;3(1):8. doi:10.11‍86/s4‍065‍8-01‍6-‍01‍44-5